[go: up one dir, main page]

NO901300L - Behandling og forbindelser. - Google Patents

Behandling og forbindelser.

Info

Publication number
NO901300L
NO901300L NO90901300A NO901300A NO901300L NO 901300 L NO901300 L NO 901300L NO 90901300 A NO90901300 A NO 90901300A NO 901300 A NO901300 A NO 901300A NO 901300 L NO901300 L NO 901300L
Authority
NO
Norway
Prior art keywords
formula
disorders
group
treatment
alkyl
Prior art date
Application number
NO90901300A
Other languages
English (en)
Other versions
NO175592B (no
NO901300D0 (no
NO175592C (no
Inventor
Harald Maschler
Barbara Ann Spicer
Harry Smith
Original Assignee
Beecham Wuelfing Gmbh & Co Kg
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Wuelfing Gmbh & Co Kg, Beecham Group Plc filed Critical Beecham Wuelfing Gmbh & Co Kg
Publication of NO901300D0 publication Critical patent/NO901300D0/no
Publication of NO901300L publication Critical patent/NO901300L/no
Publication of NO175592B publication Critical patent/NO175592B/no
Publication of NO175592C publication Critical patent/NO175592C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO901300A 1989-03-23 1990-03-21 Analogifremgangsmåte for fremstilling av terapeutisk aktive xantiner NO175592C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898906792A GB8906792D0 (en) 1989-03-23 1989-03-23 Treatment and compounds

Publications (4)

Publication Number Publication Date
NO901300D0 NO901300D0 (no) 1990-03-21
NO901300L true NO901300L (no) 1990-09-24
NO175592B NO175592B (no) 1994-07-25
NO175592C NO175592C (no) 1994-11-02

Family

ID=10653940

Family Applications (1)

Application Number Title Priority Date Filing Date
NO901300A NO175592C (no) 1989-03-23 1990-03-21 Analogifremgangsmåte for fremstilling av terapeutisk aktive xantiner

Country Status (27)

Country Link
US (4) US5734051A (no)
EP (2) EP1120417A3 (no)
JP (1) JP2510889B2 (no)
KR (1) KR0160768B1 (no)
CN (1) CN1031641C (no)
AT (1) ATE213498T1 (no)
AU (1) AU629315B2 (no)
CA (1) CA2012686C (no)
CZ (1) CZ391891A3 (no)
DE (1) DE69033915T2 (no)
DK (1) DK0389282T3 (no)
ES (1) ES2173074T3 (no)
FI (1) FI95033C (no)
GB (1) GB8906792D0 (no)
HK (1) HK1040392A1 (no)
HU (1) HU207081B (no)
IL (1) IL93832A (no)
MA (1) MA21800A1 (no)
MY (1) MY109737A (no)
NO (1) NO175592C (no)
NZ (1) NZ233021A (no)
PL (1) PL164811B1 (no)
PT (1) PT93527B (no)
SA (1) SA90100215B1 (no)
SK (1) SK391891A3 (no)
ZA (1) ZA902170B (no)
ZW (1) ZW3690A1 (no)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021422A (en) * 1989-06-08 1991-06-04 Senetek Plc Method and composition for treating hyperproliferative skin diseases using 6-aminopurine cytokinins
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
IL100088A (en) * 1990-11-21 1995-07-31 Smithkline Beecham Corp FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
AU649091B2 (en) * 1990-12-21 1994-05-12 Beecham Group Plc Xanthine derivatives
JPH06508842A (ja) 1991-07-05 1994-10-06 ビイク　グルデン　ロンベルク　ヒエーミツシエ　フアブリーク　ゲゼルシヤフト　ミツト　ベシユレンクテル　ハフツング 置換ピリダジンの皮膚病に対する使用
AU3725893A (en) * 1992-02-21 1993-09-13 Smithkline Beecham Corporation TNF inhibitors
US5342841A (en) * 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
GB9215633D0 (en) * 1992-07-23 1992-09-09 Smithkline Beecham Plc Novel treatment
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
ATE247116T1 (de) 1994-12-13 2003-08-15 Euro Celtique Sa Arylthioxanthine
EP0799040B1 (en) 1994-12-13 2003-08-20 Euroceltique S.A. Trisubstituted thioxanthines
CA2218548A1 (en) * 1995-05-19 1996-11-21 Chiroscience Limited Xanthines and their therapeutic use
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
ES2264210T3 (es) * 1997-09-05 2006-12-16 Kyowa Hakko Kogyo Co., Ltd. Derivados de xantina para el tratamiento de la isquemia cerebral.
DZ2629A1 (fr) 1997-10-23 2003-03-08 Smithkline Beecham Corp Formes polymorphes nouvelles de cipamfylline procédé pour leur préparation et compositions les contenant.
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
HU229439B1 (hu) 1999-08-21 2013-12-30 Takeda Gmbh Roflumilast és salmeterol szinergetikus kombinációja
EP2258689A1 (en) 2000-03-16 2010-12-08 Biolipox AB Benzylated PDE4 inhibitors
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6586429B2 (en) 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
HU230382B1 (hu) * 2001-02-24 2016-03-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xantinszármazékok, előállításuk és alkalmazásuk gyógyszerként
CA2446828C (en) * 2001-05-08 2011-01-04 Blanchette Rockefeller Neurosciences Institute Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
WO2003015789A2 (en) * 2001-08-15 2003-02-27 Leo Pharma A/S A pharmaceutical composition for dermal application
AR036674A1 (es) 2001-08-28 2004-09-29 Schering Corp Inhibidores de fosfodiesterasa v de guanina de policiclicos, composicion farmaceutica, y el uso de dichos compuestos para la preparacion de medicamentos para tratar desordenes fisiologicos
EP1442042A1 (en) 2001-11-09 2004-08-04 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
WO2005012303A1 (en) * 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
CA2550130A1 (en) * 2003-12-09 2005-06-23 Kyowa Hakko Kogyo Co., Ltd. Agents for preventing and/or treating higher brain dysfunctions
PL1781657T3 (pl) 2004-02-14 2013-08-30 Glaxosmithkline Ip Dev Ltd Leki o aktywności wobec receptora HM74A
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP2272848B1 (en) 2005-08-10 2012-12-26 Glaxosmithkline LLC Xanthine derivatives as selective HM74A agonists
AU2007226937A1 (en) * 2006-03-21 2007-09-27 Dr. Reddy's Laboratories Ltd. Docetaxel polymorphs and processes
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CA2810522A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
JP2010500326A (ja) 2006-08-08 2010-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのｄｐｐ−ｉｖ阻害剤としてのピロロ［３，２−ｄ］ピリミジン
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8871751B2 (en) * 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AU2010323068B2 (en) 2009-11-27 2015-09-03 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
MX2017009853A (es) 2015-01-30 2017-11-01 Shanton Pharma Co Ltd Prevencion o tratamiento de enfermedades urinarias o gotosas.
EP3280417B1 (en) 2015-04-08 2020-07-29 Lewis and Clark Pharmaceuticals, Inc. Xanthine-substituted alkynyl carbamates/reverse carbamates as a2b antagonists
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US757328A (en) * 1903-02-07 1904-04-12 Boehringer & Soehne Art of preparing xanthin derivatives.
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
US2534813A (en) * 1950-01-21 1950-12-19 Searle & Co 8-haloxanthine salts of cyclic-aminoalkyl benzohydryl ethers and the production thereof
US4120947A (en) * 1976-03-31 1978-10-17 Cooper Laboratories, Inc. Xanthine compounds and method of treating bronchospastic and allergic diseases
CH654008A5 (fr) * 1979-05-22 1986-01-31 Nestle Sa Procede de preparation de 1,3,7-trialkylxanthines.
IT1200944B (it) * 1982-08-10 1989-01-27 Malesci Sas Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4567183A (en) * 1983-03-11 1986-01-28 Analgesic Associates Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
DE3406533A1 (de) * 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US4666914A (en) * 1985-05-13 1987-05-19 Schering Corporation Anti-inflammatory and anti-allergic substituted-2,3-dihydro-6-(hydroxy)pyrimido[2,1-f]-purine-4,8(1H,9H)-diones
GB8610136D0 (en) * 1986-04-25 1986-05-29 Wellcome Found Compounds
GB8621869D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Treatment
US4879300A (en) 1986-12-22 1989-11-07 Dr. Lo. Zambeletti S.P.A. Novel piperidine derivatives
IT1197516B (it) * 1986-12-24 1988-11-30 Abc Ist Biolog Chem Spa Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono

Also Published As

Publication number Publication date
DE69033915D1 (de) 2002-03-28
HK1040392A1 (zh) 2002-06-07
EP0389282A3 (en) 1992-07-01
AU629315B2 (en) 1992-10-01
US5981535A (en) 1999-11-09
CA2012686C (en) 1999-12-07
US6180791B1 (en) 2001-01-30
EP1120417A3 (en) 2001-08-08
AU5208390A (en) 1990-09-27
KR900013962A (ko) 1990-10-22
MA21800A1 (fr) 1990-12-31
GB8906792D0 (en) 1989-05-10
KR0160768B1 (ko) 1998-12-01
EP0389282A2 (en) 1990-09-26
HU901792D0 (en) 1990-06-28
FI95033C (fi) 1995-12-11
IL93832A0 (en) 1990-12-23
NO175592B (no) 1994-07-25
FI95033B (fi) 1995-08-31
NO901300D0 (no) 1990-03-21
CN1031641C (zh) 1996-04-24
FI901447A0 (fi) 1990-03-22
ZA902170B (en) 1991-03-27
PT93527B (pt) 1996-08-30
ZW3690A1 (en) 1991-02-06
US5734051A (en) 1998-03-31
CA2012686A1 (en) 1990-09-23
SA90100215B1 (ar) 2001-10-07
HU207081B (en) 1993-03-01
JP2510889B2 (ja) 1996-06-26
PL164811B1 (pl) 1994-10-31
DK0389282T3 (da) 2002-06-03
CZ391891A3 (en) 1993-11-17
PT93527A (pt) 1990-11-07
ATE213498T1 (de) 2002-03-15
EP0389282B1 (en) 2002-02-20
CN1047502A (zh) 1990-12-05
SK391891A3 (en) 2000-12-11
MY109737A (en) 1997-05-31
DE69033915T2 (de) 2002-10-10
HUT54155A (en) 1991-01-28
IL93832A (en) 1994-07-31
NZ233021A (en) 1993-12-23
JPH02273676A (ja) 1990-11-08
NO175592C (no) 1994-11-02
EP1120417A2 (en) 2001-08-01
US6531600B1 (en) 2003-03-11
ES2173074T3 (es) 2002-10-16

Similar Documents

Publication Publication Date Title
NO901300L (no) Behandling og forbindelser.
ES2066000T3 (es) Compuestos derivados de pirimidinediona, metodo de produccion de los mismos y agentes antirritmicos que los contienen.
DE3660286D1 (en) Arylcyclobutylalkyl amines and their use as antidepressive medicines
DK570689A (da) Imidazolderivater
DK322588A (da) Cycloalkylamider af 6-substituerede (8beta)-1-alkylergoliner og fremgangsmaade til fremstilling af saadanne forbindelser
PL295932A1 (en) Method of obtaining novel bezazepine compounds
DK0485219T3 (da) Lægemidler til forebyggelse og behandling af kredsløbsorgansygdomme indeholdende spiro-3-heteroazolidinforbindelser
NO173276C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive 1,4-disubstituerte-piperidinylderivater
DK0420224T3 (da) Anthihepatopatisk middel
NO914734D0 (no) 5-amino-5,6,7,8-tetrahydrokinoliner og beslektede forbindelser, fremgangsmaate for fremstilling og anvendelse som medikamenter
MY104048A (en) New allylaminoethylazoles.
TH18165A (th) สารยับยั้งการเกิดคีโมแทกซิของอีโอซีโนฟีล